liver-cancer

Saffron compound crocin kills liver cancer cells by disrupting the RNA splicing machinery

Hepatocellular carcinoma (HCC) — primary liver cancer — is notoriously hard to treat. Researchers looked at crocin, the active compound in saffron, to understand how it fights HCC at the molecular level using time-series gene expression analysis at multiple time points after treatment.

The standout finding is that crocin consistently shuts down the spliceosome — the cellular machinery that processes RNA — across all treatment time points. This matters because abnormal RNA splicing drives cancer development in over 90% of cancers, making the spliceosome an attractive but difficult target.

Crocin also activated senescence (a state where cells stop dividing) and autophagy pathways, while suppressing cell growth. Genes linked to fatty liver disease — a precursor to HCC — were dialed down at 24 hours, suggesting possible reversal of pre-cancerous changes.

Key Findings

Crocin consistently downregulated spliceosomal machinery genes across all time points tested (2, 6, 12, 24 hours)
Senescence and autophagy pathways were activated while proliferation was suppressed
52 genes associated with non-alcoholic fatty liver disease were downregulated at 24 hours
Oncogenic transcription factor ELK1 targets were downregulated; tumor-suppressive PAX5 was upregulated
Strongest transcriptional response occurred at 2 hours with 1 mM crocin

Implications

Identifying spliceosome disruption as a key crocin mechanism is significant — it suggests a novel pharmacological approach to targeting aberrant splicing in cancer. If crocin or its derivatives can be optimized for spliceosome targeting, this could have broad applications across cancer types, not just HCC. The senescence induction mechanism is also of independent clinical interest.

Caveats

Preprint — not peer reviewed. Study conducted entirely in HepG2 cell line — a single immortalized cancer cell line, not primary cells or animal models. HepG2 has known limitations as an HCC model. Concentrations used (1–2 mM) are high and pharmacokinetic feasibility in humans is unknown. No in vivo validation.

Source: bioRxiv — 2026-04-06

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.